These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 36152808)

  • 1. Molecularly engineered siRNA conjugates for tumor-targeted RNAi therapy.
    Lee JW; Choi J; Choi Y; Kim K; Yang Y; Kim SH; Yoon HY; Kwon IC
    J Control Release; 2022 Nov; 351():713-726. PubMed ID: 36152808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current preclinical small interfering RNA (siRNA)-based conjugate systems for RNA therapeutics.
    Lee SH; Kang YY; Jang HE; Mok H
    Adv Drug Deliv Rev; 2016 Sep; 104():78-92. PubMed ID: 26514375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics.
    Kulkarni JA; Witzigmann D; Chen S; Cullis PR; van der Meel R
    Acc Chem Res; 2019 Sep; 52(9):2435-2444. PubMed ID: 31397996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Advances in Engineering Carriers for siRNA Delivery.
    Yang C; Lin ZI; Zhang X; Xu Z; Xu G; Wang YM; Tsai TH; Cheng PW; Law WC; Yong KT; Chen CK
    Macromol Biosci; 2024 Apr; 24(4):e2300362. PubMed ID: 38150293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemical and structural modifications of RNAi therapeutics.
    Ku SH; Jo SD; Lee YK; Kim K; Kim SH
    Adv Drug Deliv Rev; 2016 Sep; 104():16-28. PubMed ID: 26549145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-targeting multifunctional nanoparticles for siRNA delivery: recent advances in cancer therapy.
    Ku SH; Kim K; Choi K; Kim SH; Kwon IC
    Adv Healthc Mater; 2014 Aug; 3(8):1182-93. PubMed ID: 24577795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent Advancements in the Design of Nanodelivery Systems of siRNA for Cancer Therapy.
    Yadav DN; Ali MS; Thanekar AM; Pogu SV; Rengan AK
    Mol Pharm; 2022 Dec; 19(12):4506-4526. PubMed ID: 36409653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RNAi-based therapeutics and tumor targeted delivery in cancer.
    Kara G; Calin GA; Ozpolat B
    Adv Drug Deliv Rev; 2022 Mar; 182():114113. PubMed ID: 35063535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies for in vivo delivery of siRNAs: recent progress.
    Higuchi Y; Kawakami S; Hashida M
    BioDrugs; 2010 Jun; 24(3):195-205. PubMed ID: 20462284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging Approaches for Enabling RNAi Therapeutics.
    Mallick AM; Tripathi A; Mishra S; Mukherjee A; Dutta C; Chatterjee A; Sinha Roy R
    Chem Asian J; 2022 Aug; 17(16):e202200451. PubMed ID: 35689534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNA interference therapeutics for cancer: challenges and opportunities (review).
    Bora RS; Gupta D; Mukkur TK; Saini KS
    Mol Med Rep; 2012 Jul; 6(1):9-15. PubMed ID: 22576734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct cytoplasmic delivery of RNAi therapeutics through a non-lysosomal pathway for enhanced gene therapy.
    Zhou J; Zhang J; Chen S; Lin Q; Zhu R; Wang L; Chen X; Li J; Yang H
    Acta Biomater; 2023 Oct; 170():401-414. PubMed ID: 37625679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic delivery of siRNA by aminated poly(α)glutamate for the treatment of solid tumors.
    Polyak D; Krivitsky A; Scomparin A; Eliyahu S; Kalinski H; Avkin-Nachum S; Satchi-Fainaro R
    J Control Release; 2017 Jul; 257():132-143. PubMed ID: 27356019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. siRNA release kinetics from polymeric nanoparticles correlate with RNAi efficiency and inflammation therapy via oral delivery.
    He C; Yue H; Xu L; Liu Y; Song Y; Tang C; Yin C
    Acta Biomater; 2020 Feb; 103():213-222. PubMed ID: 31812844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current issues of RNAi therapeutics delivery and development.
    Haussecker D
    J Control Release; 2014 Dec; 195():49-54. PubMed ID: 25111131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver cancer cells as the model for developing liver-targeted RNAi therapeutics.
    Hou B; Qin L; Huang L
    Biochem Biophys Res Commun; 2023 Feb; 644():85-94. PubMed ID: 36640667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting.
    De Paula D; Bentley MV; Mahato RI
    RNA; 2007 Apr; 13(4):431-56. PubMed ID: 17329355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small-interfering RNA (siRNA)-based functional micro- and nanostructures for efficient and selective gene silencing.
    Lee SH; Chung BH; Park TG; Nam YS; Mok H
    Acc Chem Res; 2012 Jul; 45(7):1014-25. PubMed ID: 22413937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional nanostructures for effective delivery of small interfering RNA therapeutics.
    Hong CA; Nam YS
    Theranostics; 2014; 4(12):1211-32. PubMed ID: 25285170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Comprehensive Review of Small Interfering RNAs (siRNAs): Mechanism, Therapeutic Targets, and Delivery Strategies for Cancer Therapy.
    Zhang J; Chen B; Gan C; Sun H; Zhang J; Feng L
    Int J Nanomedicine; 2023; 18():7605-7635. PubMed ID: 38106451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.